Holen Sie sich die Stockscreener-App
3.27
0.91%
-0.03
Handel nachbörslich:
3.27
Acumen Pharmaceuticals Inc Aktie (ABOS) Neueste Nachrichten
Team members drive company mission, Acumen Pharmaceuticals, Inc. asserts - Traders Union
Acumen Pharma chief legal officer sells $6813 in stock By Investing.com - Investing.com Canada
Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum - Bitget
Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum - GlobeNewswire Inc.
Stock Market Recap: What is the earnings history of Acumen Pharmaceuticals Inc2026 Closing Moves & Daily Oversold Bounce Ideas - baoquankhu1.vn
Highs Report: Is Acumen Pharmaceuticals Inc a turnaround story2025 Fundamental Recap & Expert Verified Movement Alerts - baoquankhu1.vn
Aug Spikes: What is the earnings history of Acumen Pharmaceuticals Inc2025 Price Action Summary & Real-Time Volume Analysis - baoquankhu1.vn
Acumen Pharmaceuticals to Highlight New Alzheimer’s Research Progress at AD/PD™ 2026 - citybiz
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Receives $6.80 Consensus Price Target from Analysts - Defense World
Acumen Pharma chief legal officer Meisner sells $28k in shares - Investing.com Australia
Acumen (NASDAQ: ABOS) CLO exercises options and sells 9,406 shares - Stock Titan
Acumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026 - mx.advfn.com
Acumen Pharmaceuticals to showcase advances in Alzheimer's treatment at international conference on Alzheimer's and Parkinson's diseases 2026 - marketscreener.com
Acumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer's and Parkinson's Diseases 2026 - Bitget
Acumen Pharmaceuticals To Showcase Advances In Alzheimer's Treatment At International Conference On Alzheimer’S And Parkinson’S Diseases 2026 - TradingView
New Alzheimer’s treatment data explores better delivery to the brain - Stock Titan
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Acumen Pharmaceuticals (NASDAQ: ABOS) insider sells 9,406 shares - Stock Titan
ABOS Should I Buy - Intellectia AI
Profit Review: Can Acumen Pharmaceuticals Inc reach resistance levels soonTrend Reversal & Daily Chart Pattern Signals - baoquankhu1.vn
ABOS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Acumen Pharmaceuticals (NASDAQ:ABOS) Upgraded at Wall Street Zen - MarketBeat
Does Acumen Pharmaceuticals Inc. stock have upside surprise potentialJuly 2025 Spike Watch & Safe Capital Preservation Plans - mfd.ru
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Market Trends: How is BlackSky Technology Inc Equity Warrant managing supply chain issuesJuly 2025 Recap & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Sees Significant Growth in Short Interest - Defense World
ABOS Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Will Acumen Pharmaceuticals Inc. stock reach Wall Street targetsWeekly Trend Report & Daily Risk Controlled Trade Plans - mfd.ru
Decliners Report: Is Acumen Pharmaceuticals Inc a cyclical or defensive stockJuly 2025 Summary & Long-Term Growth Plans - baoquankhu1.vn
ABOS PE Ratio & Valuation, Is ABOS Overvalued - Intellectia AI
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Sees Significant Increase in Short Interest - MarketBeat
Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results - The Malaysian Reserve
Can Acumen Pharmaceuticals Inc. stock sustain institutional interest2025 Trading Volume Trends & AI Powered Buy and Sell Recommendations - mfd.ru
Doseology Sciences Launches New Energy Product Line - Intellectia AI
Acumen Pharmaceuticals celebrates team contributions - Traders Union
Brokerages Set Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Price Target at $6.80 - Defense World
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: vTv Therapeutics (VTVT), Acumen Pharmaceuticals (ABOS) - The Globe and Mail
Acumen Pharmaceuticals (NASDAQ:ABOS) Rating Lowered to Sell at Wall Street Zen - MarketBeat
While Institutions Invested in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Benefited From Last Week's 46% Gain, Private Equity Firms Stood to Gain the Most - 富途牛牛
Acumen Pharma CLO sells $53k in shares after option exercise - Investing.com Canada
Healthcare Stocks Surge in After-Hours Trading - intellectia.ai
Wall Street Analysts Adjust Ratings - intellectia.ai
Assessing Acumen Pharmaceuticals (ABOS) Valuation After New Phase 2 ALTITUDE-AD Trial Developments - Yahoo Finance
2026 Catalysts: Psychiatry, epilepsy and neurodegeneration - BioCentury
Acumen Pharmaceuticals (NASDAQ:ABOS) Price Target Raised to $7.00 at BTIG Research - MarketBeat
Are Insider Tax-Related Sales Misaligned With Acumen Pharmaceuticals’ (ABOS) Alzheimer’s Trial Progress Narrative? - Sahm
Baker Hughes To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
ABOS: BTIG Raises Price Target to $7.00, Maintains Buy Rating | - GuruFocus
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Acumen Pharmaceuticals’ Share Volatility: Insight Into Recent Developments - StocksToTrade
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Does Sabirnetug’s Phase 2 Extension and Insider Stock Sales Alter the Bull Case for ABOS? - Yahoo Finance
Analysts Predict Up to 400% Spike for These 2 ‘Strong Buy’ Penny Stocks - Yahoo Finance
Acumen Pharmaceuticals CEO sells shares worth $21993 - Investing.com Nigeria
Acumen Pharmaceuticals CLO sells shares worth $16,720 By Investing.com - Investing.com South Africa
Acumen Pharma CFO Zuga sells shares worth $7.6k By Investing.com - Investing.com Canada
Acumen Pharmaceuticals CEO sells shares worth $21993 By Investing.com - Investing.com South Africa
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):